Filing Flows › Medifast (MED) › Capital expenditures
Medifast (MED) capital expenditures by quarter
Medifast's capital expenditures were $427K in Q3 2026 (third quarter 2026), -56% from Q2 2026. Over the last 5 quarters it ranged from $427K (Q3 2026) to $1.5M (Q1 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $427K | -56% | -69% |
| Q2 2026 | $969K | -12% | — |
| Q1 2026 | $1.1M | -20% | -28% |
| Q3 2025 | $1.4M | -10% | — |
| Q1 2025 | $1.5M | — | — |
Q3 2026 at a glance
Medifast, Q3 2026: revenue $72.0M (-19% year over year), operating margin -26.9%, net loss $17.5M, operating cash flow $3.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Medifast's capital expenditures?
Medifast's capital expenditures were $427K in Q3 2026 (third quarter 2026), -56% from Q2 2026.
How has Medifast's capital expenditures changed?
Over the last 5 quarters it ranged from $427K (Q3 2026) to $1.5M (Q1 2025).